COLLEGE STATION, Texas, Nov. 3, 2025 /PRNewswire/ -- Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector CDMO specializing in advanced therapies, today announced a strategic partnership ...
As more cell, gene and immunotherapy applications emerge for lentiviral vectors, demand for their production continues to rise. With its move last week into a larger manufacturing facility, CDMO ...
The "Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024-2029" report has been added to ResearchAndMarkets.com's offering. This analysis provides detailed ...
COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology Inc. (Matica Bio), a CDMO specializing in viral vector development and manufacturing, announced the signing of a Letter of Intent (LOI) ...
CDMO ProBio, the biologics subsidiary of GenScript, expanded its plasmid DNA and viral vector production capacity with the opening of new manufacturing facility in Hopewell, New Jersey. The site, ...
FRANKFURT, Germany, VIENNA and SEONGNAM, South Korea, Nov. 5, 2025 /PRNewswire/ -- IDT Biologika GmbH (IDT), the European subsidiary of SK bioscience, has embarked on a full-scale drive to expand its ...
" Matica Bio stood out as the clear CDMO of choice for Calidi project due to their deep experience with viral vector and their ability to handle complex viral programs with precision," said Eric Poma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results